Tilray Brands, Inc.’s TLRY TLRY medical cannabis division, Tilray Medical, has received approval and verification from The Natural Health Science Foundation ("NHSF") of its flagship product, Tilray Purified Oral Solution (“OS”) CBD100, to be used in clinical trials in Australia and New Zealand.
George Polimenakos, general manager, Tilray Medical ANZ (Australia and New Zealand) stated, "We are extremely pleased with this outcome and proud to provide EU-GMP certified products to patients in Australia and New Zealand. Having our product quality validated by the NHSF demonstrates Tilray's commitment to delivering the highest quality cannabis products to our patients.”
The NHSF is an independent not-for-profit organization that assists patients, consumers, and healthcare professionals in making informed natural medicine choices based on science. NHSF believes natural medicines will be valuable in modern scientific medical practice if they follow best practices of quality, safety, and efficacy through transparency and evidence.
Nigel Pollard, chairman, Natural Health Science Foundation, stated, "Tilray Purified OS CBD100 has been thoroughly assessed by independent experts and has met the quality & equivalence standards of the Natural Health Science Foundation. This means the product has a basis of reproducibility which serves as a valid medical intervention, from a scientific point of view, for patient use and to test in a clinical trial."
In addition to the approval received from the NHSF standard of scientific reproducibility for clinical trials, the New Zealand Ministry of Health has verified that the Tilray Purified OS CBD100 has met its quality standards to ensure consistency of the products that medical practitioners prescribe to their patients.
Photo: Benzinga; Sources: courtesy of jarmoluk, lindsayfox via Pixabay
Related News
Tilray Follows Curaleaf, Gets Approval To Enter Medical Cannabis Market In Poland
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
